Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea.
暂无分享,去创建一个
[1] B. Pasternack,et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. , 1980, The New England journal of medicine.
[2] J. Potter,et al. Pharmacogenetic screening and therapeutic drugs. , 2002, Clinica chimica acta; international journal of clinical chemistry.
[3] J. Lafitte,et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S‐methyltransferase gene (TPMT) in a European population , 1998, British journal of pharmacology.
[4] C. Heng,et al. Thiopurine Methyltransferase Polymorphisms in a Multiracial Asian Population and Children With Acute Lymphoblastic Leukemia , 2002, Journal of pediatric hematology/oncology.
[5] W. Evans,et al. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient , 1993, The Lancet.
[6] H. Koo,et al. Erythrocyte thiopurine methyltransferase activity in a Korean population. , 1996, British journal of clinical pharmacology.
[7] Ching-Hon Pui,et al. Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance , 1997, Annals of Internal Medicine.
[8] R. Weinshilboum,et al. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.
[9] G. Fick,et al. Azathioprine and 6-Mercaptopurine in Crohn Disease , 1995, Annals of Internal Medicine.
[10] M. Kamm,et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. , 1993, Gut.
[11] K. Chiba,et al. Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, *3B and *3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositus. , 2001, British journal of clinical pharmacology.
[12] H. McLeod,et al. Thiopurine Methyltransferase Genotype Predicts Therapy-Limiting Severe Toxicity from Azathioprine , 1998, Annals of Internal Medicine.
[13] J. Gummert,et al. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient , 1993, The Lancet.
[14] P. Corey,et al. Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .
[15] W. Evans,et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. , 1991, The Journal of pediatrics.
[16] J. Aarbakke,et al. Thiopurine methyltransferase activity in a Korean population sample of children , 1996, Clinical pharmacology and therapeutics.
[17] J. Esdaile,et al. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. , 2002, The Journal of rheumatology.
[18] M. Suarez‐Almazor,et al. Azathioprine for treating rheumatoid arthritis. , 2000, The Cochrane database of systematic reviews.
[19] R. Weinshilboum,et al. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. , 1978, Clinica chimica acta; international journal of clinical chemistry.
[20] E. Utsi,et al. Interethnic difference in thiopurine methyltransferase activity , 1992, Clinical pharmacology and therapeutics.
[21] M. Suarez‐Almazor,et al. Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and longterm effectiveness. , 1995, The Journal of rheumatology.
[22] W. Evans,et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. , 1996, American journal of human genetics.
[23] C. Fischer,et al. Inhibition of thiopurine S-methyltransferase activity by impurities in commercially available substrates: a factor for differing results of TPMT measurements , 1999, European Journal of Clinical Pharmacology.
[24] V. Ho,et al. Immunosuppressive agents in dermatology. An update. , 1998, Dermatologic clinics.
[25] L. Lennard. Clinical implications of thiopurine methyltransferase--optimization of drug dosage and potential drug interactions. , 1998, Therapeutic drug monitoring.
[26] M. Relling,et al. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. , 1995, Blood.
[27] R. Weinshilboum,et al. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms , 1997, Clinical pharmacology and therapeutics.
[28] R. Weinshilboum. Methylation pharmacogenetics: thiopurine methyltransferase as a model system. , 1992, Xenobiotica; the fate of foreign compounds in biological systems.
[29] N. Shear,et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. , 2000, Journal of the American Academy of Dermatology.
[30] W. Kalow,et al. Thiopurine S‐methyltransferase activity in a Chinese population , 1993, Clinical pharmacology and therapeutics.
[31] R. Weinshilboum,et al. Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6‐thioguanine nucleotide concentrations , 1987, Clinical pharmacology and therapeutics.
[32] W. Kalow. Pharmacogenetics : heredity and the response to drugs , 1962 .
[33] D. Collier,et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. , 1999, Pharmacogenetics.
[34] W. Evans,et al. Pharmacogenetics as a Molecular Basis for Individualized Drug Therapy: The Thiopurine S-methyltransferase Paradigm , 1999, Pharmaceutical Research.